News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,427 Results
Type
Article (13926)
Company Profile (299)
Press Release (247202)
Section
Business (79368)
Career Advice (151)
Deals (13196)
Drug Delivery (34)
Drug Development (50323)
Employer Resources (31)
FDA (5678)
Job Trends (5115)
News (144150)
Policy (10018)
Tag
Academia (901)
Alliances (21516)
Alzheimer's disease (750)
Approvals (5652)
Artificial intelligence (67)
Bankruptcy (97)
Best Places to Work (4517)
Biotechnology (245)
Breast cancer (107)
Cancer (856)
Cardiovascular disease (67)
Career advice (132)
CAR-T (68)
Cell therapy (208)
Clinical research (40059)
Collaboration (278)
Compensation (121)
COVID-19 (1005)
C-suite (76)
Cystic fibrosis (66)
Data (960)
Diabetes (81)
Diagnostics (1206)
Earnings (29002)
Events (47152)
Executive appointments (227)
FDA (6022)
Funding (292)
Gene editing (63)
Gene therapy (161)
GLP-1 (306)
Government (1064)
Healthcare (6540)
Infectious disease (1041)
Inflammatory bowel disease (98)
IPO (7192)
Job creations (860)
Job search strategy (127)
Layoffs (186)
Legal (1374)
Lung cancer (123)
Lymphoma (57)
Manufacturing (79)
Medical device (2558)
Medtech (2559)
Mergers & acquisitions (6125)
Metabolic disorders (243)
Neuroscience (987)
NextGen Class of 2024 (2000)
Non-profit (845)
Northern California (1056)
Obesity (134)
Opinion (91)
Parkinson's disease (70)
Patents (59)
People (25070)
Phase I (14118)
Phase II (18628)
Phase III (11799)
Pipeline (358)
Postmarket research (851)
Preclinical (5971)
Radiopharmaceuticals (205)
Rare diseases (196)
Real estate (1409)
Regulatory (8260)
Research institute (930)
Southern California (949)
Startups (1964)
United States (8405)
Vaccines (164)
Weight loss (78)
Date
Today (41)
Last 7 days (434)
Last 30 days (1670)
Last 365 days (20565)
2024 (20081)
2023 (22415)
2022 (26822)
2021 (27806)
2020 (23360)
2019 (16224)
2018 (11741)
2017 (13756)
2016 (11856)
2015 (14362)
2014 (10393)
2013 (7486)
2012 (7543)
2011 (7619)
2010 (7428)
Location
Africa (146)
Asia (16948)
Australia (2848)
California (2392)
Canada (783)
China (193)
Colorado (88)
Connecticut (99)
Europe (36395)
Florida (261)
Georgia (68)
Illinois (145)
Indiana (60)
Kansas (55)
Maryland (320)
Massachusetts (1897)
Michigan (54)
Minnesota (99)
New Jersey (609)
New York (666)
North Carolina (412)
Northern California (1056)
Ohio (81)
Pennsylvania (459)
South America (207)
Southern California (949)
Texas (267)
Washington State (243)
261,427 Results for "irx therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Io Therapeutics, Inc., announces presentation of data from studies of its RAR gamma agonist compound IRX5010 in treatment of a mouse model of triple negative breast cancer, demonstrating combination treatment effects with an anti-PDL-1 monoclonal antibody checkpoint inhibitor
December 12, 2024
·
3 min read
Press Releases
Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers
November 8, 2024
·
3 min read
Business
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging
September 18, 2024
·
3 min read
Press Releases
Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound
July 8, 2024
·
2 min read
Drug Development
Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis (ALS)
July 16, 2024
·
4 min read
Drug Development
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease
July 10, 2024
·
5 min read
Lone Star Bio
Io Therapeutics, Inc., Announces Publication of Data on a Novel Compound Promoting Anti-Cancer Immune Responses
Io Therapeutics, Inc., announced the publication in Scientific Reports – Nature Publishing Group, of results from studies done with the company’s novel anti-cancer compound IRX4647, an agonist of the retinoic acid nuclear receptor gamma, discovered in the company’s oncology drug program.
September 12, 2023
·
2 min read
Drug Development
Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer
Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity.
July 26, 2022
·
5 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Regulatory
FDA Warns Applied Therapeutics of ‘Objectionable Conditions’ in Govorestat Study
The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical trial—including a dosing error for govorestat—claims that the company said it had already addressed.
December 4, 2024
·
2 min read
·
Tristan Manalac
1 of 26,143
Next
